BRABEVACNOR1
BRABEVACNOR1
AMBEV S/A ON
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 88.242.500.000 | 89.452.700.000 | 1.4% |
| Cost of Revenue | 42.864.100.000 | 43.615.100.000 | 1.7% |
| Gross Profit | 45.378.400.000 | 45.837.600.000 | 1.0% |
| 23.055.800.000 | 24.330.800.000 | 5.2% | |
| Operating Income | 22.322.600.000 | 21.506.800.000 | 3.8% |
| Pretax Income | 19.421.700.000 | 19.487.300.000 | 0.3% |
| Net Income Common Stockholders | 15.503.400.000 | 14.437.200.000 | 7.4% |
| -- | -- | -- | |
| -- | -- | -- |